{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T04:41:07Z","timestamp":1746160867462},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2020,2,24]]},"DOI":"10.18632\/aging.102858","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T22:51:03Z","timestamp":1582584663000},"page":"3899-3910","source":"Crossref","is-referenced-by-count":3,"title":["Clinical burden of autosomal dominant polycystic kidney disease"],"prefix":"10.18632","volume":"12","author":[{"given":"Peir-Haur","family":"Hung","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chia-Yi, Taiwan"},{"name":"Department of Applied Life Science and Health, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Hung","family":"Lin","sequence":"additional","affiliation":[{"name":"Division of Pediatric Immunology and Nephrology, Department of Pediatrics, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan"},{"name":"Department of Pediatrics, Zhongxing Branch, Taipei City Hospital, Taipei, Taiwan"},{"name":"College of Science and Engineering, Fu Jen Catholic University, New Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuan-Yu","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hsin","family":"Muo","sequence":"additional","affiliation":[{"name":"Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu-Chi","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Taichung Veterans General Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Hsiang","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Jung","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Medical Research, China Medical University Hospital, Taichung, Taiwan"},{"name":"Department of Public Health, China Medical University, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease.","volume":"36","author":"Pirson","year":"2007","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1681\/ASN.V5122048","article-title":"Causes of death in autosomal dominant polycystic kidney disease.","volume":"5","author":"Gabow","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/0272-6386(95)90096-9","article-title":"A century of mortality in five large families with polycystic kidney disease.","volume":"2","author":"Vandenbroucke","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"4","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1097\/01.ASN.0000018407.60002.B9","article-title":"Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.","volume":"1","author":"Tison","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"5","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","article-title":"No effect of enalapril on progression in autosomal dominant polycystic kidney disease.","volume":"1","author":"Westendorp","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"6","first-page":"133","article-title":"Better understanding of ADPKD results in potential new treatment options: ready for the cure?","volume":"2","author":"Gansevoort","year":"2008","journal-title":"J Nephrol"},{"key":"7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"34","author":"Shahinfar","year":"2001","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.","volume":"34","author":"Raz","year":"2001","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.","volume":"35","author":"Remuzzi","year":"1999","journal-title":"Lancet"},{"key":"10","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.","volume":"34","author":"The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","year":"1997","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency.","volume":"35","author":"Geng","year":"2006","journal-title":"N Engl J Med"},{"key":"12","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.","volume":"1","author":"Jiang","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"13","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1093\/ndt\/16.11.2152","article-title":"Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.","volume":"1","author":"Blauw","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"14","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0272-6386(99)70182-4","article-title":"Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration.","volume":"3","author":"Garc\u00eda","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"15","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/sj.ki.5000302","article-title":"Pentoxifylline ameliorates proteinuria through suppression of renal monocyte chemoattractant protein-1 in patients with proteinuric primary glomerular diseases.","volume":"6","author":"Tsai","year":"2006","journal-title":"Kidney Int"},{"key":"16","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/ndt\/gfs417","article-title":"Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.","volume":"2","author":"Fick-Brosnahan","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3265\/Nefrologia.pre2011.Dec.11177","article-title":"Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease.","volume":"3","author":"Lu\u00f1o","year":"2012","journal-title":"Nefrologia"},{"key":"18","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.2215\/CJN.09731110","article-title":"Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease.","volume":"6","author":"Torres","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"19","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1046\/j.1523-1755.2003.00918.x","article-title":"Recurrence of intracranial aneurysms in autosomal-dominant polycystic kidney disease.","volume":"6","author":"Gabow","year":"2003","journal-title":"Kidney Int"},{"key":"20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrneph.2015.128","article-title":"Vascular complications in autosomal dominant polycystic kidney disease.","volume":"1","author":"Watnick","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1053\/j.ackd.2010.01.006","article-title":"Treatment strategies and clinical trial design in ADPKD.","volume":"1","author":"Torres","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1573402111309010002","article-title":"Cardiovascular complications in autosomal dominant polycystic kidney disease.","volume":"9","author":"Ecder","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10157-012-0741-0","article-title":"Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies.","volume":"1","author":"Nitta","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"24","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.","volume":"8","author":"Torra","year":"2015","journal-title":"Kidney Int"},{"key":"25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/08860220601038892","article-title":"Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease.","volume":"2","author":"Ecder","year":"2007","journal-title":"Ren Fail"},{"key":"26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease.","volume":"9","author":"Schrier","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease.","volume":"4","author":"Kincaid-Smith","year":"2010","journal-title":"Scand J Urol Nephrol"},{"key":"28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2369-15-63","article-title":"Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease.","volume":"1","author":"Ahn","year":"2014","journal-title":"BMC Nephrol"},{"key":"29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2188\/jea.10.403","article-title":"Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers.","volume":"1","author":"Murayama","year":"2000","journal-title":"J Epidemiol"},{"key":"30","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community.","volume":"1","author":"Levey","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"31","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals.","volume":"5","author":"Timio","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"32","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000353730","article-title":"Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease.","volume":"12","author":"Oymak","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2012.03.011","article-title":"Uric acid, allopurinol therapy, and mortality in patients with acute heart failure\u2014results of the Acute HEart FAilure Database registry.","volume":"2","author":"\u0160pinar","year":"2012","journal-title":"J Crit Care"},{"key":"34","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/rheumatology\/kep069","article-title":"Allopurinol and mortality in hyperuricaemic patients.","volume":"4","author":"Choi","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"35","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/annrheumdis-2014-205269","article-title":"Allopurinol initiation and all-cause mortality in the general population.","volume":"7","author":"Choi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"36","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.","volume":"17","author":"Chung","year":"2015","journal-title":"JAMA Intern Med"},{"key":"37","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jid.2016.02.808","article-title":"Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions.","volume":"13","author":"Wu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"38","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.","volume":"7","author":"Lin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"39","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1097\/01.ASN.0000034909.10994.8A","article-title":"Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.","volume":"1","author":"Tsai","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"40","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1681\/ASN.2005010001","article-title":"Additive antiproteinuric effect of pentoxifylline in patients with type 2 diabetes under angiotensin II receptor blockade: a short-term, randomized, controlled trial.","volume":"1","author":"Garc\u00eda","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"41","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1053\/j.ajkd.2008.11.026","article-title":"Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.","volume":"5","author":"Yuan","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1681\/ASN.2014010012","article-title":"Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.","volume":"2","author":"Garc\u00eda","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"43","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/ije\/dyu149","article-title":"Good practices for quantitative bias analysis.","volume":"4","author":"Greenland","year":"2014","journal-title":"Int J Epidemiol"},{"key":"44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3747\/co.v18i3.858","article-title":"Uptake of novel medical therapies in the general population.","volume":"1","author":"Rapoport","year":"2011","journal-title":"Curr Oncol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.102858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T11:45:37Z","timestamp":1665920737000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.102858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,29]]}},"alternative-id":["102858","32096480"],"URL":"https:\/\/doi.org\/10.18632\/aging.102858","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]}}}